Japanese Journal of Gastroenterology and Hepatology Review Article ISSN 2435-1210 Volume 6 Review of Cancer - Related Cachexia: Defnition, Physiopathology and Treatment Rioja P 1* , Valencia G 1 , Moreno J 2 , Neciosup S 1 and Gomez H 1 1 Department of Medical Oncology. Instituto Nacional de Enfermedades Neoplasicas. Lima, Peru 2 Department of Medical Oncology. Instituto Regional de Enfermedades Neoplasicas. Trujillo, La Libertad, Peru * Corresponding author: Patricia Rioja, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Angamos Este Avenue 2520, Surquillo, Lima, Peru, Tel: +51 2016500x2208, E-mail: patyriojavi@gmail.com Received: 11 May 2021 Accepted: 04 June 2021 Published: 11 June 2021 Copyright: ©2021 Rioja P, This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially. Citation: Rioja P. Review of Cancer - Related Cachexia: Defnition, Phys- iopathology and Treatment. Japanese J Gstro Hepato. 2021; V6(15): 1-5 1 Keywords: Cancer- related cachexia; Physiopathology cachexia; Refractory cancer cachexia; Megestrol acetate; Corticosteroids 1. Abstract The deterioration in nutrition status is frequently seen in cancer pa- tients. Cancer- related Cachexia (CC) is a common multifactorial con- dition that highly impacts on survival and quality of life of cancer patients. CC has been categorized into three phases: pre-cachexia, cachexia and refractory cachexia. The risk of progression depends on several factors related to the type of cancer or clinical stage. The pathophysiology of CC involves more complex mechanisms than simply caloric defciency. The process is mainly mediated by proin- fammatory cytokines/neuroendocrine hormones, the alteration of the synthesis/degradation of the hepatic proteins and of the skeletal muscles as well as the lipolysis of the adipocytes. Nowadays, no ef- fective medical intervention completely reverses cachexia; however, an adequate nutritional support remains a mainstay of cachexia ther- apy. In this review we outline the recent knowledge of mechanisms involved of CC, which will enable the understanding of pharma- cologic interventions that have been developed to the present day improving quality of life and more importantly improving survival in cancer patients. 2. Introduction Cancer - related cachexia (CC) is a life-threatening condition asso- ciated with several pathologies [1]. It was frst described in 2006 as a complex syndrome that can be related to weight loss or patho- logical wasting of muscle or in combination with fat tissue. CC is multifactorial and its physiopathology leads to an imbalance between catabolism and anabolism independent of food intake [2]. CC has been recognized as a relevant adverse effect in cancer patients, with an incidence of up to 80% in advanced cancers, being considered as an unfavorable prognosis marker for survival [3, 4]. Multiple factors contribute to the complex physiopathology of CC, being the reduc- tion of food intake a fundamental (and in some cases, predominant) component in the weight loss of these patients [5]. It is important to timely recognize the onset of cachexia in order to implement various interventions aimed at reducing or delaying its impact, since a specifc intervention in one of the phases of cachexia (pre-cachexia, cachexia and refractory cachexia) can have a greater impact on survival and quality of life (QoL) [6]. 3. Defnition and Diagnostic Criteria CC is defned as a multifactorial syndrome characterized by a contin- uous loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully resolved by conventional nutritional support and leads to progressive functional impairment [7]. The following criteria have been established for its recognition: weight loss greater than 5% in the last 6 months, body mass index (BMI) < 20, skeletal ap- pendicular mass index consistent with sarcopenia (males < 7.26 kg/ m2; females < 5.45 kg/m2), and any weight loss > 2% [8] (Table 1).